XELOX + SOX (Peking Union Medical College Hospital)

XELOX + SOX refers to a treatment grouping of two standard-of-care chemotherapy regimens, XELOX (capecitabine and oxaliplatin) and SOX (S-1 and oxaliplatin), utilized in the management of locally advanced gastric cancer. This specific designation is associated with clinical research conducted by Peking Union Medical College Hospital, specifically a Phase 2 trial (NCT04343248) evaluating whether patients with poor histologic regression after neoadjuvant therapy benefit from switching to a modified regimen (Paclitaxel/Cisplatin) versus continuing these original regimens. XELOX combines the oral fluoropyrimidine prodrug capecitabine with the platinum-based agent oxaliplatin. SOX combines S-1 (a composite of tegafur, gimeracil, and oteracil) with oxaliplatin. Both regimens function by inhibiting DNA synthesis and inducing cellular apoptosis through DNA cross-linking and thymidylate synthase inhibition.

Other names

XELOX/SOXCapeOx/SOXCapecitabine + Oxaliplatin or S-1 + Oxaliplatin